查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1859716

药物基因体学技术市场预测至2032年：按产品/服务、技术、应用、最终用户和地区分類的全球分析

Pharmacogenomics Technology Market Forecasts to 2032 - Global Analysis By Product & Service (Instruments, Reagents & Kits, Software, Services and Consumables), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球药物基因体学技术市场预计到 2025 年将达到 84 亿美元，到 2032 年将达到 164 亿美元，预测期内复合年增长率为 10.1%。

药物基因体学技术是研究和应用个别基因组成如何影响药物反应的学科。透过分析影响药物代谢、疗效和安全性的基因变异，该技术能够制定针对每位患者的个人化医疗策略。它整合了基因组学、生物资讯学和分子生物学，以预测药物反应、最大限度地减少副作用并优化治疗效果。药物基因体学技术广泛应用于药物研发、临床试验和患者照护，以指南剂量调整和药物选择。其应用旨在提高治疗效果、降低医疗成本并促进精准医疗的发展。

根据世界卫生组织 (WHO) 2023 年 5 月发布的报告，心血管疾病、糖尿病、癌症和呼吸系统疾病等慢性疾病预计将占全球整体死亡人数的 86%，比 2019 年增加了 90%。

对个人化医疗的需求日益增长

医生和研究人员正在利用基因资讯为每位患者量身定制药物剂量和治疗方案。该平台支援肿瘤学、心臟病学、精神病学和感染疾病等领域的基因型鉴定、定序和生物标记分析。与电子健康记录和临床决策支援工具的整合提高了准确性和工作流程效率。医院网路、学术中心和生物製药研发管线对预测性和病患特异性诊断的需求日益增长。这些趋势正在推动该平台在个人化医疗生态系统中的部署。

临床应用有限

儘管研究结果有力地检验了基因检测的有效性，但许多医疗系统缺乏将基因检测整合到常规诊疗中的基础设施、训练和奖励。医生在解读检测结果并将其与处方指南和临床方案相协调方面面临许多挑战。支付方不愿为缺乏明确成本效益证据或长期疗效数据的检测项目买单。监管政策的模糊性和零散的实施进一步延缓了临床整合和相关人员的协调。这些限制因素阻碍了基因检测平台的成熟和在医疗系统中的主流推广应用。

活性化研发活动

政府学术机构和生物製药公司正在投资进行大规模人群药物反应建模和生物标记发现研究。相关平台支援将高通量定序与机器学习和多体学相结合，以提高预测准确性和治疗相关性。临床试验、药物开发和转化研究对可扩展且可互通的工具的需求日益增长。诊断公司和製药公司之间的伙伴关係正在加速共同开发，并促进与监管机构的合作。这些趋势正在推动以研究主导、以创新为中心的药物基因体学平台的整体发展。

不同族群代表性不足

大多数资料集和演算法都偏向欧洲裔人群，这限制了其普适性和治疗效果。少数族群群体在参与基因研究和检测计画以及对其信任方面面临许多障碍。缺乏全面的数据阻碍了全球人群中生物标记的发现、剂量优化和不利事件预测。监管机构和倡导团体呼吁制定多元化要求和伦理框架来弥补这些差距。这些限制持续限制药物基因组学生态系统中平台的表现和公平应用。

新冠疫情的影响：

疫情扰乱了临床试验诊断和药物基因体学技术的供应链。封锁和资源重新分配延缓了样本采集、检测方法开发和监管审批。然而，随着研究人员探索药物反应、疫苗效力和疾病严重程度的遗传因素，人们对个人化医疗的兴趣日益浓厚。对远距检测、数位医疗和人群药物基因体学的投资加速了平台创新和普及。消费者和临床群体对基因检测和精准医疗的认知度不断提高。这些变化强化了对药物基因组学基础设施和转化研究的长期投资。

预计试剂和试剂盒细分市场在预测期内将成为最大的细分市场。

预计在预测期内，试剂和试剂盒领域将占据最大的市场份额，因为它们在整个药物基因体学工作流程中发挥基因型鉴定、测序和生物标记分析的基础性作用。平台为临床和研究环境中的DNA提取、PCR扩增和变异检测提供标准化且可扩展的解决方案。与自动化设备和生物资讯流程的整合提高了通量准确性和可重复性。医院实验室、学术中心和生物製药临床试验对经过验证的、符合监管标准的试剂的需求正在增长。供应商提供针对特定疾病的伴随诊断试剂盒和针对特定治疗领域的模组化试剂盒。

预计在预测期内，生物製药公司板块的复合年增长率将最高。

预计在预测期内，生物製药公司将实现最高成长率，因为它们将药物基因体学融入药物发现的临床试验和监管申报流程中。相关平台支援临床前和临床阶段的患者分层、剂量优化和不利事件预测。与真实数据人工智慧引擎和监管框架的整合，能够优化试验设计和治疗标靶性。免疫肿瘤学和中枢神经系统药物研发管线正在推动以生物标记为导向的精准开发的需求。这些因素共同促进了生物製药主导药物基因组学技术的广泛应用。

占比最大的地区：

由于北美拥有先进的研究基础设施、积极的监管参与以及药物基因组学技术的临床应用，预计在预测期内，北美将占据最大的市场份额。企业和学术机构正在肿瘤学、精神病学和感染疾病计画中部署定序和决策支援工具的平台。对人群基因组学报销框架和数位健康整合的投资有助于扩充性和可及性。主要诊断机构、生物製药公司和监管机构的存在正在推动创新和标准化。各公司正根据FDA的指导、NIH的资助和支付方的参与情况调整其平台策略。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于医疗现代化、基因组医学和生物製药领域的投资在整个区域经济中的整合。中国、印度、日本和韩国等国家正在公共卫生、学术研究和临床新兴企业扩展药物基因体学学平台。政府支持的倡议正在推动个人化医疗领域的基础建设、新创企业孵化和国际合作。本地企业正在提供经济高效且在地化的解决方案，以满足疾病特征和合规性需求。肿瘤学、感染疾病和慢性病领域对可扩展且符合当地文化的药物基因体学平台的需求日益增长。这些趋势正在推动亚太地区药物基因组学创新和应用的成长。

免费客製化服务：

订阅本报告的用户可免费获得以下自订选项之一：

  • 公司简介
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 二手研究资料
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球药物基因体学技术市场（按产品和服务划分）

  • 装置
  • 试剂和试剂盒
  • 软体
  • 服务
  • 消耗品

6. 全球药物基因体学技术市场（依技术划分）

  • 聚合酵素链锁反应（PCR）
  • DNA序列分析
  • 微阵列
  • 质谱分析
  • 电泳
  • 原位杂交
  • 生物资讯学和人工智慧平台
  • 样品製备与萃取技术
  • 其他技术

7. 全球药物基因体学技术市场（按应用划分）

  • 肿瘤学
  • 感染疾病
  • 心血管疾病
  • 神经系统疾病
  • 精神病学
  • 疼痛管理
  • 其他用途

8. 全球药物基因体学技术市场（依最终用户划分）

  • 医院和诊所
  • 学术和研究机构
  • 诊断检查室
  • 生物製药公司
  • 其他最终用户

9. 全球药物基因体学技术市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十一章 企业概况

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Illumina Inc.
  • QIAGEN NV
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Myriad Genetics Inc.
  • 23andMe Holding Co.
  • GenScript Biotech Corporation
  • Eurofins Scientific SE
  • Beckman Coulter Inc.
  • Becton, Dickinson and Company
  • PerkinElmer Inc.
  • SomaLogic Inc.
  • Color Health Inc.
Product Code: SMRC31940

According to Stratistics MRC, the Global Pharmacogenomics Technology Market is accounted for $8.4 billion in 2025 and is expected to reach $16.4 billion by 2032 growing at a CAGR of 10.1% during the forecast period. Pharmacogenomics technology is the study and application of how an individual's genetic makeup influences their response to drugs. By analyzing variations in genes that affect drug metabolism, efficacy, and safety, this technology enables the development of personalized medicine strategies tailored to each patient. It integrates genomics, bioinformatics, and molecular biology to predict drug response, minimize adverse effects, and optimize therapeutic outcomes. Pharmacogenomics technology is widely used in drug discovery, clinical trials, and patient care, guiding dosage adjustments and drug selection. Its implementation aims to enhance treatment effectiveness, reduce healthcare costs, and advance precision medicine.

According to a World Health Organization (WHO) report published in May 2023, chronic diseases such as cardiovascular diseases, diabetes, cancer, and respiratory illnesses are expected to cause 86% of all deaths globally, representing a 90% increase since 2019.

Market Dynamics:

Driver:

Rising demand for personalized medicine

Physicians and researchers are leveraging genetic insights to tailor drug selection dosage and treatment plans for individual patients. Platforms support genotyping sequencing and biomarker analysis across oncology cardiology psychiatry and infectious diseases. Integration with electronic health records and clinical decision support tools enhances precision and workflow efficiency. Demand for predictive and patient-specific diagnostics is rising across hospital networks academic centers and biopharma pipelines. These dynamics are propelling platform deployment across personalized medicine ecosystems.

Restraint:

Limited clinical implementation

Despite strong research validation many healthcare systems lack infrastructure training and incentives to integrate genetic testing into routine care. Physicians face challenges in interpreting results and aligning them with formulary guidelines and clinical protocols. Payers remain hesitant to cover tests without clear cost-benefit evidence or long-term outcomes data. Regulatory ambiguity and fragmented adoption further delay clinical integration and stakeholder alignment. These constraints continue to hinder platform maturity and mainstream deployment across healthcare systems.

Opportunity:

Increased research and development activities

Government's academic institutions and biopharma firms are investing in population-scale studies drug response modeling and biomarker discovery. Platforms support high-throughput sequencing machine learning and multi-omics integration to enhance predictive accuracy and therapeutic relevance. Demand for scalable and interoperable tools is rising across clinical trials drug development and translational research. Partnerships between diagnostics firms and pharmaceutical companies are accelerating co-development and regulatory alignment. These trends are fostering growth across research-driven and innovation-centric pharmacogenomics platforms.

Threat:

Underrepresentation of diverse populations

Most datasets and algorithms are biased toward populations of European ancestry limiting generalizability and therapeutic efficacy. Minority groups face barriers in access participation and trust across genetic research and testing programs. Lack of inclusive data hampers biomarker discovery dosage optimization and adverse event prediction across global populations. Regulatory bodies and advocacy groups are calling for diversity mandates and ethical frameworks to address these gaps. These limitations continue to constrain platform performance and equitable adoption across pharmacogenomics ecosystems.

Covid-19 Impact:

The pandemic disrupted clinical trials diagnostics and supply chains across pharmacogenomics technologies. Lockdowns and resource reallocation delayed sample collection assay development and regulatory review. However interest in personalized medicine surged as researchers explored genetic factors in drug response vaccine efficacy and disease severity. Investment in remote testing digital health and population genomics accelerated platform innovation and accessibility. Public awareness of genetic testing and precision medicine increased across consumer and clinical segments. These shifts are reinforcing long-term investment in pharmacogenomics infrastructure and translational research.

The reagents & kits segment is expected to be the largest during the forecast period

The reagents & kits segment is expected to account for the largest market share during the forecast period due to their foundational role in enabling genotyping sequencing and biomarker analysis across pharmacogenomics workflows. Platforms offer standardized and scalable solutions for DNA extraction PCR amplification and variant detection across clinical and research settings. Integration with automation instruments and bioinformatics pipelines enhances throughput accuracy and reproducibility. Demand for validated and regulatory-grade reagents is rising across hospital labs academic centers and biopharma trials. Vendors offer disease-specific panels companion diagnostics and modular kits tailored to therapeutic areas.

The biopharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biopharmaceutical companies segment is predicted to witness the highest growth rate as firms integrate pharmacogenomics into drug discovery clinical trials and regulatory submissions. Platforms support patient stratification dose optimization and adverse event prediction across preclinical and clinical phases. Integration with real-world data AI engines and regulatory frameworks enhances trial design and therapeutic targeting. Demand for precision-driven and biomarker-aligned development is rising across oncology immunology and CNS pipelines. These dynamics are accelerating growth across biopharma-led pharmacogenomics technology adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure regulatory engagement and clinical adoption across pharmacogenomics technologies. Enterprises and academic institutions deploy platforms across oncology psychiatry and infectious disease programs with integrated sequencing and decision support tools. Investment in population genomics reimbursement frameworks and digital health integration supports scalability and accessibility. Presence of leading diagnostics firms biopharma companies and regulatory bodies drives innovation and standardization. Firms align platform strategies with FDA guidance NIH funding and payer engagement.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization genomic medicine and biopharma investment converge across regional economies. Countries like China India Japan and South Korea scale pharmacogenomics platforms across public health academic research and clinical diagnostics. Government-backed initiatives support infrastructure development startup incubation and international collaboration across personalized medicine. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. Demand for scalable and culturally aligned pharmacogenomics platforms is rising across oncology infectious diseases and chronic conditions. These trends are accelerating regional growth across pharmacogenomics innovation and deployment.

Key players in the market

Some of the key players in Pharmacogenomics Technology Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN N.V., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Myriad Genetics Inc., 23andMe Holding Co., GenScript Biotech Corporation, Eurofins Scientific SE, Beckman Coulter Inc., Becton, Dickinson and Company, PerkinElmer Inc., SomaLogic Inc. and Color Health Inc.

Key Developments:

In October 2025, Roche unveiled major advances in its Sequencing by Expansion (SBX) technology at the ASHG Conference. The platform enabled bulk RNA sequencing, methylation mapping, and spatial multiomics, unlocking pharmacogenomic insights previously inaccessible with short-read platforms. Roche's SBX system was used by Broad Clinical Labs to set a GUINNESS WORLD RECORD(TM) for fastest DNA sequencing in under four hours.

In February 2025, Illumina unveiled its multiomics roadmap, expanding into spatial transcriptomics, single-cell analysis, CRISPR screening, and methylation profiling. These technologies were built on Illumina's core sequencing platforms and supported pharmacogenomic applications in drug response prediction and biomarker discovery. The launch positioned Illumina as a leader in integrated omics for precision medicine.

Product & Services Covered:

  • Instruments
  • Reagents & Kits
  • Software
  • Services
  • Consumables

Technologies Covered:

  • Polymerase Chain Reaction (PCR)
  • DNA Sequencing
  • Microarray
  • Mass Spectrometry
  • Electrophoresis
  • In-Situ Hybridization
  • Bioinformatics & AI Platforms
  • Sample Preparation & Extraction Technologies
  • Other Technologies

Applications Covered:

  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Psychiatry
  • Pain Management
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Diagnostic Laboratories
  • Biopharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmacogenomics Technology Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Reagents & Kits
  • 5.4 Software
  • 5.5 Services
  • 5.6 Consumables

6 Global Pharmacogenomics Technology Market, By Technology

  • 6.1 Introduction
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 DNA Sequencing
  • 6.4 Microarray
  • 6.5 Mass Spectrometry
  • 6.6 Electrophoresis
  • 6.7 In-Situ Hybridization
  • 6.8 Bioinformatics & AI Platforms
  • 6.9 Sample Preparation & Extraction Technologies
  • 6.10 Other Technologies

7 Global Pharmacogenomics Technology Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Infectious Diseases
  • 7.4 Cardiovascular Diseases
  • 7.5 Neurological Disorders
  • 7.6 Psychiatry
  • 7.7 Pain Management
  • 7.8 Other Applications

8 Global Pharmacogenomics Technology Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Academic & Research Institutes
  • 8.4 Diagnostic Laboratories
  • 8.5 Biopharmaceutical Companies
  • 8.6 Other End Users

9 Global Pharmacogenomics Technology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 F. Hoffmann-La Roche Ltd.
  • 11.2 Thermo Fisher Scientific Inc.
  • 11.3 Illumina Inc.
  • 11.4 QIAGEN N.V.
  • 11.5 Agilent Technologies Inc.
  • 11.6 Bio-Rad Laboratories Inc.
  • 11.7 Myriad Genetics Inc.
  • 11.8 23andMe Holding Co.
  • 11.9 GenScript Biotech Corporation
  • 11.10 Eurofins Scientific SE
  • 11.11 Beckman Coulter Inc.
  • 11.12 Becton, Dickinson and Company
  • 11.13 PerkinElmer Inc.
  • 11.14 SomaLogic Inc.
  • 11.15 Color Health Inc.

List of Tables

  • Table 1 Global Pharmacogenomics Technology Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Pharmacogenomics Technology Market Outlook, By Product & Service (2024-2032) ($MN)
  • Table 3 Global Pharmacogenomics Technology Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Pharmacogenomics Technology Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 5 Global Pharmacogenomics Technology Market Outlook, By Software (2024-2032) ($MN)
  • Table 6 Global Pharmacogenomics Technology Market Outlook, By Services (2024-2032) ($MN)
  • Table 7 Global Pharmacogenomics Technology Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Pharmacogenomics Technology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 9 Global Pharmacogenomics Technology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 10 Global Pharmacogenomics Technology Market Outlook, By DNA Sequencing (2024-2032) ($MN)
  • Table 11 Global Pharmacogenomics Technology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 12 Global Pharmacogenomics Technology Market Outlook, By Mass Spectrometry (2024-2032) ($MN)
  • Table 13 Global Pharmacogenomics Technology Market Outlook, By Electrophoresis (2024-2032) ($MN)
  • Table 14 Global Pharmacogenomics Technology Market Outlook, By In-Situ Hybridization (2024-2032) ($MN)
  • Table 15 Global Pharmacogenomics Technology Market Outlook, By Bioinformatics & AI Platforms (2024-2032) ($MN)
  • Table 16 Global Pharmacogenomics Technology Market Outlook, By Sample Preparation & Extraction Technologies (2024-2032) ($MN)
  • Table 17 Global Pharmacogenomics Technology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 18 Global Pharmacogenomics Technology Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Pharmacogenomics Technology Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global Pharmacogenomics Technology Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 21 Global Pharmacogenomics Technology Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 22 Global Pharmacogenomics Technology Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 23 Global Pharmacogenomics Technology Market Outlook, By Psychiatry (2024-2032) ($MN)
  • Table 24 Global Pharmacogenomics Technology Market Outlook, By Pain Management (2024-2032) ($MN)
  • Table 25 Global Pharmacogenomics Technology Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global Pharmacogenomics Technology Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Pharmacogenomics Technology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 28 Global Pharmacogenomics Technology Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 29 Global Pharmacogenomics Technology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 30 Global Pharmacogenomics Technology Market Outlook, By Biopharmaceutical Companies (2024-2032) ($MN)
  • Table 31 Global Pharmacogenomics Technology Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.